Trial Profile

A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK1059615 in Patients With Solid Tumors or Lymphoma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 23 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 1059615 (Primary)
Indications Lymphoma; Solid tumours
Focus Adverse reactions
Sponsors GlaxoSmithKline; GSK

Most Recent Events

12 Aug 2009 Actual number of patients (11) added as reported by ClinicalTrials.gov
12 Aug 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov
15 Jul 2008 Status changed from initiated to recruiting according to M.D. Anderson website.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com